SMTL ID : 6v7c.2 (1 other biounit)

Human Arginase1 Complexed with Bicyclic Inhibitor Compound 3

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 1.80 Å

Oligo State

homo-trimer

Ligands

6 x MN: MANGANESE (II) ION(Non-covalent)

MN.1: 6 residues within 4Å: Chain A: D.124, H.126, D.232, D.234 Ligands: MN.2, QR1.3 5 PLIP interactions: 5 interactions with chain A Metal complexes: A:D.124, A:H.126, A:D.232, A:D.234, A:D.234 MN.2: 6 residues within 4Å: Chain A: H.101, D.124, D.128, D.232 Ligands: MN.1, QR1.3 4 PLIP interactions: 4 interactions with chain A Metal complexes: A:H.101, A:D.124, A:D.128, A:D.232 MN.4: 6 residues within 4Å: Chain B: H.101, D.124, D.128, D.232 Ligands: MN.5, QR1.6 4 PLIP interactions: 4 interactions with chain B Metal complexes: B:H.101, B:D.124, B:D.128, B:D.232 MN.5: 6 residues within 4Å: Chain B: D.124, H.126, D.232, D.234 Ligands: MN.4, QR1.6 5 PLIP interactions: 5 interactions with chain B Metal complexes: B:D.124, B:H.126, B:D.232, B:D.234, B:D.234 MN.7: 6 residues within 4Å: Chain C: D.124, H.126, D.232, D.234 Ligands: MN.8, QR1.9 5 PLIP interactions: 5 interactions with chain C Metal complexes: C:D.124, C:H.126, C:D.232, C:D.234, C:D.234 MN.8: 6 residues within 4Å: Chain C: H.101, D.124, D.128, D.232 Ligands: MN.7, QR1.9 4 PLIP interactions: 4 interactions with chain C Metal complexes: C:H.101, C:D.124, C:D.128, C:D.232

3 x QR1: {3-[(3aR,4S,5S,6aR)-5-azaniumyl-5-carboxyoctahydrocyclopenta[c]pyrrol-2-ium-4-yl]propyl}(trihydroxy)borate(1-)(Non-covalent)

QR1.3: 17 residues within 4Å: Chain A: H.101, D.124, H.126, D.128, N.130, S.137, H.141, G.142, D.181, D.183, E.186, D.232, D.234, T.246, E.277 Ligands: MN.1, MN.2 17 PLIP interactions: 17 interactions with chain A Hydrophobic interactions: A:H.126 Hydrogen bonds: A:N.130, A:S.137, A:D.181, A:D.183, A:D.183, A:T.246, A:E.277 Water bridges: A:D.128, A:T.135, A:T.135, A:T.135, A:S.137, A:N.139, A:D.183, A:T.246, A:T.246 QR1.6: 17 residues within 4Å: Chain B: H.101, D.124, H.126, D.128, N.130, S.137, H.141, G.142, D.181, D.183, E.186, D.232, D.234, T.246, E.277 Ligands: MN.4, MN.5 16 PLIP interactions: 16 interactions with chain B Hydrophobic interactions: B:H.126 Hydrogen bonds: B:N.130, B:S.137, B:D.181, B:D.183, B:D.183, B:T.246, B:E.277, B:E.277 Water bridges: B:T.127, B:S.137, B:N.139, B:G.142, B:G.142, B:D.183, B:T.246 QR1.9: 17 residues within 4Å: Chain C: H.101, D.124, H.126, D.128, N.130, S.137, H.141, G.142, D.181, D.183, E.186, D.232, D.234, T.246, E.277 Ligands: MN.7, MN.8 12 PLIP interactions: 12 interactions with chain C Hydrophobic interactions: C:H.126 Hydrogen bonds: C:N.130, C:S.137, C:H.141, C:D.181, C:D.183, C:D.183, C:E.277 Water bridges: C:D.128, C:S.137, C:T.246, C:T.246

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Mitcheltree, M.J. et al., Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer Immunotherapy. Acs Med.Chem.Lett. (2020)

Release Date

2020-05-06

Peptides

Arginase-1: ABC

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
C

B
D

C
F

Arginase-1

Related Entries With Identical Sequence